Abstract: A computer-implemented system for processing image data. The system comprises: a sensor operable to capture image data comprising an image of an environment of the sensor; and a processing circuit comprising: a processor; and a computer-readable storage medium comprising computer-readable instructions which, when executed, cause the processor to: receive the image data from the sensor; process the image data using a first path through a neural network to obtain first data, the first path configured to indicate a presence in the environment of one or more objects of a predetermined object type; process the image data using a second path through a neural network to obtain second data, the second path configured to indicate a presence in the environment of one or more object characteristics corresponding to the predetermined object type; and generate output data using the first and second data, wherein the first and second paths are arranged to be enable the first and second data to be obtained in parallel.

Abstract: The present invention provides a novel algorithm for salience detection based on a dual rail antagonistic structure to predict where people look in images in a free-viewing condition. Furthermore, the proposed algorithm can be effectively applied to both still and moving images in visual media without any parameter tuning in real-time.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to pancreatic cancers and the use of biomarkers in biological samples for the diagnosis of such conditions, in particular pancreatic ductal adenocarcinoma. The biomarker panel comprises LYVE1, REG1 and TFF1. Methods of treatment are also provided, as well as kits useful in the diagnosis and treatment of pancreatic ductal adenocarcinoma. The present invention is particularly useful in detecting early-stage PDAC.

Abstract: A surgical tool for use in the treatment of anal fistulas includes an elongate, flexible probe having a channel running there through; a seton attached to a proximal end of the probe; and a wire located within the channel, and movable along the channel; wherein: the probe has a first stiffness and the wire has a second stiffness, the first stiffness being less than the second stiffness.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The present invention provides a multilayer matrix comprising at least two layers in which the first layer comprises a bioresorbable material and the second layer comprises a bioadhesive material, wherein the second layer contains cells. A method for producing a multilayer matrix and the use of a multilayer matrix are also provided.

Abstract: Disclosed herein is a sound synthesis system for generating a user defined synthesised sound effect, the system comprising: a receiver of user defined inputs for defining a sound effect; a generator of control parameters in dependence on the received user defined inputs; a plurality of sound effect objects, wherein each sound effect object is arranged to generate a different class of sound and each sound effect object comprises a sound synthesis model arranged to generate a sound in dependence on one or more of the control parameters; a plurality of audio effect objects, wherein each audio effect object is arranged to receive a sound from one or more sound effect objects and/or one or more other audio effect objects, process the received sound in dependence on one or more of the control parameters and output the processed sound; a scene creation function arranged to receive sound output from one or more sound effect objects and/or audio effect objects and to generate a synthesised sound effect in dependence o

Abstract: The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.

Abstract: The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to pancreatic cancers and the use of biomarkers in biological samples for the diagnosis of such conditions, in particular pancreatic ductal adenocarcinoma. The biomarker panel comprises LYVE1, REG1 and TFF1. Methods of treatment arc also provided, as well as kits useful in the diagnosis and treatment of pancreatic ductal adenocarcinoma. The present invention is particularly useful in detecting early-stage PDAC.

Abstract: The present invention provides an anti-angiogenic peptide comprising an amino acid sequence having at least 70% identity to amino acid residues 123-140 of SEQ ID NO 1 or amino acid residues 24-141 of SEQ ID NO 2. The invention also provides nucleic acid constructs encoding such peptides, and vectors and cells comprising such nucleic acid constructs. The invention further provides pharmaceutical compositions comprising the peptides or nucleic acid constructs of the invention, and the use of peptides, nucleic acid constructs or pharmaceutical compositions of the invention to treat diseases associated with angiogenesis.

Abstract: The present invention relates to glycolysis-activating agents. The present invention also relates to the treatment or prevention of diseases or medical conditions, in particular immune-related diseases or medical conditions. In particular, the present invention also relates to agents for use in the treatment or prevention of a disease or medical condition, which treatment or prevention is mediated via the trafficking of endogenous regulatory T cells (Tregs).

Abstract: The present invention provides a crystalline salt of chlorhexidine chloride having a spherical morphology under Scanning Electron Microscopy (SEM) comprising a chloride anion and a cation selected from the group consisting of calcium, sodium, potassium, magnesium, zinc, strontium or iron, processes for the preparation of the salt, compositions, pharmaceutical compositions and uses thereof in medicine. Also provided are crystalline forms of the salt and fibres comprising the same.

Abstract: The present invention provides an antibody which comprises a variable heavy (VH) chain comprising CDR1, CDR2 and CDR3, and/or a variable light (VL) chain comprising CDR1, CDR2 and CDR3, wherein the CDRs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in Tables 1 and 2 or Tables 1 A and 2 A.

Abstract: The present invention provides a method for determining whether a Rheumatoid Arthritis (RA) patient is susceptible to treatment with a B cell targeted therapy, which method comprises the step of analyzing B cells and/or germinal center-like structures (GC-LS) in a synovial tissue sample from the patient; wherein a patient whose synovial tissue sample is B cell rich and/or GC-LS negative is determined to be susceptible to treatment with the B cell targeted therapy, whereas a patient whose synovial tissue sample is B-cell poor and/or GC-LS positive is determined to be resistant to treatment with the B cell targeted therapy.

Abstract: The present invention relates to pancreatic cancers and the use of biomarkers in biological samples for the diagnosis of such conditions, in particular pancreatic ductal adenocarcinoma. The biomarker panel comprises LYVE1, REG1 and TFF1. Methods of treatment are also provided, as well as kits useful in the diagnosis and treatment of pancreatic ductal adenocarcinoma. The present invention is particularly useful in detecting early-stage PDAC.

Abstract: The present disclosure provides a method for generating an affinity reagent library against a target protein which interacts with a ligand, which comprises the following steps; •i) determining one or more structural element(s) of the ligand which are involved in ligand: target protein interaction; •ii) producing a library of peptides which retain these structural element(s); and •iii) grafting each peptide from the library of peptides into a portion of the affinity reagent molecule such that it may interact with the target protein, in order to produce an affinity reagent library.

Abstract: The present invention relates to miRNA biomarkers for use in the diagnosis of pancreatic diseases, in particular pancreatic cancers and pre-cancerous diseases, such as pancreatic ductal adenocarcinoma (PDAC), in particular the early detection of PDAC. The miRNA biomarkers are miR-143, miR-223, miR-204, miR-30e, miR-26a, miR-30a, miR-30b and miR-106b. They may be combined with protein biomarkers. The present invention also provides methods of diagnosis and treatment of PDAC and related diseases, and kits for the early detection of PDAC based on the expression levels of the biomarkers in biological samples, in particular urine samples.